高树庚，1966年生，籍贯山东，胸外科专家，肿瘤医院副院长，主任医师，博士生导师。1984年考入山东医科大学临床医学专业，1989年获得学士学位。1995年在中国协和医科大学肿瘤学专业攻读硕士学位，从事胸部肿瘤相关研究。2002年在中国协和医科大学肿瘤学专业攻读博士学位，从事胸部肿瘤临床和转化研究。2011年进入永利集团3044官网欢迎您肿瘤研究所进行博士后研究工作，主要从事胸部肿瘤相关研究。1995年升为主治医师。2003年为副主任医师，2008年为主任医师。

肺癌微创外科治疗，早期非小细胞肺癌术式的创新及改进；局部晚期非小细胞肺癌新辅助治疗模式构建；探索基于外周血ctDNA改变在肺癌复发转移预测中的应用及其相关机制，推动基础研究的临床转化。

1. Guo W#, Zhou B#, Yang Z#, Liu X, Huai Q, Guo L, Xue X, Tan F, Li Y, Xue Q, Gao S*, He J. Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma. EBioMedicine. 2022 Oct;84:104281. (IF=11.205)

2. Zhou B#, Bie F#, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhao J*, Gao S*. RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer. EBioMedicine. 2022 Oct;84:104268. (IF=11.205)

3. Qiu B#, Ji Y#, Zhang F, Bai G, Xue Q, Polaczek M, Tosi D, Koike T, Gao S*, He J. Outcomes and experience of anatomical partial lobectomy. J Thorac Cardiovasc Surg. 2022 Sep;164(3):637-647.e1. (IF=6.439)

4. Guo W#, Chen X, Liu R, Liang N, Ma Q, Bao H, Xu X, Wu X, Yang S, Shao Y, Tan F, Xue Q, Gao S*, He J. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine. 2022 Jul;81:104131. (IF=11.205)

5. Zhang F#, Guo W#, Zhou B#, Wang S, Li N, Qiu B, Lv F, Zhao L, Li J, Shao K, Xue Q, Gao S*, He J. Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2022 Jul;17(7):909-920. (IF=20.121)

6. Zhou B#, Zang R, Zhang M, Song P, Liu L, Bie F, Peng Y, Bai G, Gao S*. Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study. EBioMedicine. 2022 Apr;78:103951. (IF=11.205)

7. Wang S#, Yuan P#, Mao B#, Li N, Ying J, Tao X, Tang W, Zhang L, Geng X, Zhang F, Xue Q, Wu L, Zhang H*, Gao S*, He J. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. NPJ Precis Oncol. 2022 Jan 13;6(1):2. (IF=10.092)

8. Qiu B#, Guo W#, Zhang F, Lv F, Ji Y, Peng Y, Chen X, Bao H, Xu Y, Shao Y, Tan F, Xue Q, Gao S*, He J. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021 Nov 19;12(1):6770. (IF=17.694)

9. Yang Z#, Xu J, Li L, Li R, Wang Y, Tian Y, Guo W, Wang Z, Tan F, Ying J, Jiao Y, Gao S*, Wang J*, Gao Y*, He J*. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nat Commun. 2020 Sep 28;11(1):4878. (IF=14.919)

10. Gao S#, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, Shao K, Lei W, Wang D, Lv F, Zhao L, Zhang F, Zhao Z, Su K, Tan F, Gao Y, Sun N, Wu D, Yu Y, Ling Y, Wang Z, Duan C, Tang W, Zhang L, He S, Wu N, Wang J, He J*. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020 May;15(5):816-826. (IF=15.609, ESI)